Neumora Therapeutics (NMRA) Total Liabilities (2022 - 2026)

Neumora Therapeutics' Total Liabilities history runs 5 years deep, the most recent figure standing at $83.2 million for Q1 2026.

• In Q1 2026, Total Liabilities rose 193.11% year-over-year to $83.2 million; the TTM figure through Mar 2026 stood at $83.2 million (up 193.11% YoY), while the FY2025 annual figure was $87.2 million, up 191.48% from the prior year.
• Total Liabilities for Q1 2026 stood at $83.2 million, down from $87.2 million in the prior quarter.
• The five-year high for Total Liabilities was $87.2 million in Q4 2025, with the low at $23.2 million in Q2 2024.
• The 5-year median for Total Liabilities is $30.9 million (2024), against an average of $40.4 million.
• The sharpest annual moves came in 2023 and 2026: Total Liabilities decreased 7.75% in 2023, then soared 193.11% in 2026.
• Neumora Therapeutics' Total Liabilities stood at $29.4 million in 2022, then decreased by 7.75% to $27.1 million in 2023, then advanced by 10.28% to $29.9 million in 2024, then soared by 191.48% to $87.2 million in 2025, then retreated by 4.56% to $83.2 million in 2026.
• Business Quant data shows NMRA's Total Liabilities at $83.2 million in Q1 2026, $87.2 million in Q4 2025, and $45.7 million in Q3 2025.